Diabetic Retinopathy (Retinopathy, Diabetic)

Subscribe to Selected New Research on Diabetic Retinopathy

5108 relevant articles (213 outcomes, 871 trials/studies) found for this Disease

Description: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Also Known As:

Retinopathy, Diabetic; Diabetic Retinopathies; Retinopathies, Diabetic

Relationship Network

Disease Context: Research Results

Eye Diseases: 1323

Retinal Diseases: 702

Diabetic Retinopathy: 5108

Cardiovascular Diseases: 20552

Vascular Diseases: 7633

Diabetic Angiopathies: 947

Diabetic Retinopathy: 5108

Endocrine System Diseases: 398

Diabetes Mellitus: 23818

Diabetes Complications: 2426

Diabetic Angiopathies: 947

Diabetic Retinopathy: 5108

Related Diseases

1.	Macular Edema
2.	Macular Degeneration (Age-Related Maculopathy)
3.	Retinal Vein Occlusion
4.	Diabetes Mellitus
5.	Blindness (Hysterical Blindness)

Experts

1.	Simó, Rafael: 10 articles (06/2008 - 09/2002)
2.	Hernández, Cristina: 10 articles (06/2008 - 09/2002)
3.	Mitamura, Yoshinori: 9 articles (05/2008 - 06/2002)
4.	Klein, Ronald: 9 articles (05/2008 - 02/2002)
5.	Petrovic, Daniel: 8 articles (03/2008 - 01/2003)
6.	Simó, R: 7 articles (09/2008 - 01/2000)
7.	Aiello, Lloyd Paul: 7 articles (06/2008 - 12/2002)
8.	Petrovic, Mojca Globocnik: 7 articles (03/2008 - 01/2003)
9.	Ohno, Shigeaki: 7 articles (10/2007 - 06/2002)
10.	Hernández, C: 6 articles (09/2008 - 01/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Diabetic Retinopathy:

1.	Retinaldehyde (Retinal)IBA 07/01/2003 - "One eye with retinal macroaneurysm and another with proliferative diabetic retinopathy did not show marked improvement immediately following membranotomy. " 09/01/2004 - "CONCLUSIONS: The analysis of retinal photography in digital format can be considered a valid method with respect to the gold standard, and the severity indicators analysed can play a guiding role in obtaining greater prevalences of derivable diabetic retinopathy, but cannot be used as an isolated test for making clinical decisions." 05/01/2004 - "CONCLUSIONS: Two-field digital retinal photography is effective in diabetic retinopathy grading and it can replace 35-mm retinal photography. " 03/01/2004 - "This raises the possibility that PKC inhibition therapy may be only regionally effective in treating retinal pathophysiology associated with diabetic retinopathy." 03/01/2007 - "OBJECTIVE: To evaluate the efficacy of nonmydriatic digital retinal images for determining diabetic retinopathy. " Order ALL the reference details at left...
2.	ArgonIBA 09/30/1991 - "The Argon-photocoagulator is in daily use in all Eye Departments in Norway and the main group of patients treated are those with diabetic retinopathy. " 06/01/1993 - "To investigate the efficacy and possible side effects of orange dye laser light in the treatment of diabetic retinopathy, we performed a prospective, controlled clinical study comparing argon blue-green and orange dye laser light. " 05/01/1989 - "[Nyctometric studies in argon laser coagulation in patients with diabetic retinopathy]" 11/01/1986 - "[Long-term study following panretinal argon laser coagulation in proliferative diabetic retinopathy]" 09/01/2007 - "CONCLUSION: There was no significant alteration in the contrast sensitivity of patients with diabetic retinopathy after panphotocoagulation with argon laser in the studied period." Order ALL the reference details at left...
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/01/2008 - "Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?" 11/01/2007 - "CONCLUSIONS: These results indicate that MEM could be useful for the treatment of ocular diseases, including diabetic retinopathy with neurodegeneration, elevated vitreoretinal VEGF protein levels, and increased BRB breakdown. " 02/01/2002 - "The inhibition of VEGF bioactivity may prove useful in the treatment of the early diabetic retinopathy." 11/01/2009 - "Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabetic retinopathy: preliminary study." 10/01/2009 - "CONCLUSION: Our study suggests that the 936 C/T polymorphism of the VEGF gene may be an important factor determining plasma VEGF levels and that its polymorphism is related with diabetic retinopathy. " Order ALL the reference details at left...
4.	Insulin (Novolin)FDA Link 06/01/1985 - "Diabetic retinopathy after one year of improved metabolic control obtained by continuous subcutaneous insulin infusion (CSII)." 09/01/2009 - "METHODS: An open-label, 5 year, randomised (1:1), multicentre, stratified, parallel-group study conducted in the USA and Canada enrolled individuals with type 2 diabetes and either no or non-proliferative retinopathy (less than severe; Early Treatment Diabetic Retinopathy Study [ETDRS] level less than 53 in both eyes) who were treated with oral hypoglycaemic agents (OHAs) alone, insulin alone or OHAs with insulin for >/=3 months prior to study entry and a baseline HbA(1c) level of 6.0-12.0%. " 02/01/2008 - "OBJECTIVE: To study the prevalence of microalbuminuria and its association with more severe diabetic retinopathy in a group of insulin-dependent diabetic patients. " 01/01/2007 - "Taking advantage of the availability of a group of young lean, normotensive and generally normolipidemic subjects in Bangladeshi population, the present study was undertaken to investigate the relationship between insulin secretory capacity and microvascular damage in the pathogenesis of diabetic retinopathy. " 12/01/2004 - "RESULTS: Two randomized trials, the Diabetes Control and Complications Trial and the UK Prospective Diabetes Study (UKPDS), provided evidence that intensive glycemic control obtained with either intensive insulin or oral therapy effectively slowed the onset and progression of diabetic retinopathy, nephropathy, and neuropathy in patients with type 1 and type 2 diabetes. " Order ALL the reference details at left...
5.	bevacizumab FDA Link 06/01/2007 - "CONCLUSION: Intravitreal bevacizumab was safe and effective in treatment of proliferative diabetic retinopathy. " 05/01/2009 - "METHODS: An institutional study was carried out with consecutive patients with diabetic retinopathy and macula-involving TRD of recent (3 months) onset who were randomly assigned to PPV only (PPV group) or PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (bevacizumab (BEV)/PPV group). " 11/01/2006 - "Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)." 04/01/2009 - "CONCLUSION: Intravitreal bevacizumab before PRP can be an effective adjunctive treatment to PRP in the treatment of high-risk proliferative diabetic retinopathy, especially if there is not CSME." 04/01/2009 - "METHODS: In forty-one eyes with high-risk proliferative diabetic retinopathy, intravitreal bevacizumab (1.25 mg/0.05 mL) before PRP (Plus group) or PRP alone (PRP group) was performed. " Order ALL the reference details at left...
6.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 08/01/2004 - "Improved analogues with increased selectivity and modified bi-specific analogues are currently emerging and may help to make the use of somatostatin analogues a more realistic option in the treatment of diabetic retinopathy." 02/01/2004 - "The somatostatin analog promises to be safe and effective treatment for severe diabetic retinopathy. " 02/01/2004 - "The development of somatostatin analogs with increased selectivity for receptor subtypes will provide improved outcomes in the management of patients with diabetic retinopathy." 09/01/2007 - "Somatostatin analogues provide an elegant pharmacological principal to modify the high-risk form of proliferative diabetic retinopathy. " 01/01/2007 - "Use of long-acting somatostatin analogue treatment in diabetic retinopathy." Order ALL the reference details at left...
7.	Octreotide (Sandostatin)FDA LinkGeneric 01/01/2001 - "Efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. " 04/01/2000 - "The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study." 03/01/2004 - "Evidence from animal models, and clinical trials in patients with diabetic retinopathy, suggest that octreotide can delay, and to some extent reverse diabetic retinopathy." 01/01/2005 - "The potential role of octreotide in the treatment of diabetic retinopathy." 03/01/2004 - "111In octreotide retention in the orbit of a patient with diabetic retinopathy." Order ALL the reference details at left...
8.	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/01/2007 - "Intravitreal triamcinolone acetonide for diabetic retinopathy." 12/01/2004 - "Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy." 03/01/2004 - "Intravitreal injection of triamcinolone acetonide may be useful for treatment of optic nerve head neovascularization in patients with proliferative diabetic retinopathy." 03/01/2006 - "PURPOSE: To evaluate prospectively the efficacy of a single sub-Tenon's capsule injection of triamcinolone acetonide (TA) against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe diabetic retinopathy and good vision. " 05/01/2009 - "RESULTS: Used alone, intravitreal triamcinolone acetonide (IVTA) seems to have some short-term efficacy against DME, but longer-term outcomes (< or = 3 years) using IVTA monotherapy showed a lesser benefit than focal/grid laser treatment in a prospective RCT done by the Diabetic Retinopathy Clinical Research Network. " Order ALL the reference details at left...
9.	KryptonIBA 07/01/1995 - "AIMS--The therapeutic efficacy of the continuous wave (CW) Nd:YAG laser (working in the free running mode) was investigated in proliferative diabetic retinopathy (PDR) comparing it with a conventional laser source such as the krypton laser. " 09/01/1999 - "OBJECTIVE: To evaluate the clinical effects of krypton yellow laser photocoagulation for cystoid macular edema (CME) in nonproliferative diabetic retinopathy (NPDR). " 09/01/1999 - "[A clinical observation of krypton yellow laser photocoagulation for cystoid macular edema in nonproliferative diabetic retinopathy]" 01/01/1982 - "A similar clinical trial to compare the efficacy of krypton laser to the proven efficacy of argon laser in the treatment of proliferative diabetic retinopathy is still anticipated." 06/01/1979 - "A comparative study of the relative efficacy of the krypton and argon lasers in the treatment of disc new vessels in diabetic retinopathy was made. " Order ALL the reference details at left...
10.	Aldehyde Reductase (Aldose Reductase)IBA 11/01/1995 - "Aldose reductase inhibitors may be beneficial in ameliorating the similar vascular lesions characteristic of human diabetic retinopathy, though the mechanism remains obscure." 04/01/2005 - "The study aimed to determine whether the aldose reductase gene is involved in diabetic retinopathy in the Tunisian population. " 04/01/2005 - "[Association study between diabetic retinopathy and aldose reductase gene polymorphism in Tunisians]" 03/01/2005 - "In the association study, a relationship between the aldose reductase (AC)n gene polymorphism and the development of diabetic retinopathy in patients with Type 2 diabetes were studied. " 05/01/1991 - "At the present time, results of the only study of aldose reductase inhibition and diabetic retinopathy reported in humans were negative. " Order ALL the reference details at left...

Therapies and Procedures

1.	Light Coagulation 09/01/1993 - "Reducing the stimulus for angiogenesis by destroying the ischaemic retina also forms the basis of the most effective treatment of diabetic retinopathy by photocoagulation. " 02/01/1994 - "Thus, color Doppler imaging may help to identify those diabetic patients who are at high risk of developing severe diabetic retinopathy so that early photocoagulation treatment can be initiated." 04/15/1990 - "Five consecutive patients with proliferative diabetic retinopathy who were treated successfully with panretinal photocoagulation subsequently developed a central retinal artery obstruction. " 04/01/2005 - "INTRODUCTION: Panretinal photocoagulation proved to be effective in preventing complications related to vasoproliferative diabetic retinopathy. " 08/09/1985 - "Although photocoagulation is no cure for diabetic retinopathy, it slows down or, in favourable cases, prevents further progression. " Order ALL the reference details at left...
2.	Lasers (Laser) 01/01/1995 - "The fact that laser treatment is effective in diabetic retinopathy has been proven clinically. " 12/01/2007 - "The trials have demonstrated a significant reduction in visual loss and need for laser treatment in patients with moderate to severe diabetic retinopathy over a 3-year period. " 08/01/2005 - "These findings may help to explain the high efficacy of laser treatment in diabetic retinopathy." 05/01/2007 - "Laser treatment is effective for diabetic macular oedema and proliferative diabetic retinopathy. " 10/01/1997 - "Laser treatment is remarkably effective against diabetic retinopathy. " Order ALL the reference details at left...
3.	Vitrectomy 10/01/1983 - "Visual loss from the complications of advanced diabetic retinopathy now can be managed more effectively by surgical vitrectomy with a significant reduction in operative and postoperative ocular morbidity. " 02/01/2008 - "CONCLUSION: NEI VFQ-25 quantitatively clarified that vitrectomy for diabetic retinopathy is effective in increasing the QOL of diabetic retinopathy patients." 08/01/1995 - "The authors' findings are consistent with those of the Diabetic Retinopathy Vitrectomy Study Group, and patients can expect both improved visual acuity and anatomic success." 09/01/2007 - "With the improvement in instruments, techniques, and drugs, the results of vitrectomy in proliferative diabetic retinopathy are improving." 01/01/1990 - "In remote terms, visual acuity improved in 85.7% in group I, and in 45.5%--in group II. Vitrectomy with preliminary cryocoagulation is indicated to all patients with complicated far-advanced proliferative diabetic retinopathy." Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 11/01/2001 - "CONCLUSIONS: An early subnormal superior hemiretinal DeltaPO(2) after treatment appears to be a good predictor of the risk of development of retinopathy, as well as for assessing therapeutic efficacy in experimental diabetic retinopathy." 04/01/2002 - "Ophthalmic evaluation revealed that 80% of patients showed stable or improved vision 3 months after treatment and that 27% of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time. " 04/01/2008 - "After treatment, the mean distance UCVA improved by a mean of 2.1 lines on the Early Treatment Diabetic Retinopathy Study logMAR chart. " 07/01/2008 - "Early Treatment Diabetic Retinopathy Study (ETDRS) scores, and foveal thicknesses measured using third generation ocular coherence tomography (OCT), were evaluated at baseline and at 1 month and 3 months after treatment. " 11/01/2004 - "Tests included best corrected visual acuity for far and near with Early Treatment Diabetic Retinopathy Study (ETDRS) and Jaeger charts, multifocal (mf)ERG, central visual field analysis, optical coherence tomography (OCT), and angiography, before surgery, and 1 month and 3 months after treatment, and at 3-month intervals thereafter. " Order ALL the reference details at left...
5.	Laser Therapy (Surgery, Laser) 01/01/1999 - "The milestone clinical trials establishing the efficacy of laser therapy and the parameters for its clinical application in diabetic retinopathy are outlined." 07/01/2004 - "Metabolic control was not optimal and one patient developed proliferative diabetic retinopathy, necessitating laser surgery. " 04/01/2004 - "Emphasis on diabetic screening, diabetic therapy, and appropriate laser therapy of diabetic retinopathy must be explored." 09/01/2003 - "Of those with diabetic retinopathy who were advised to have treatment at the time of registration, only 20% were treated with laser therapy." 01/01/2003 - "SST analogues have been successfully used to treat proliferative diabetic retinopathy (PDR) that is unresponsive to laser therapy and to retard the progression of severe nonproliferative retinopathy to PDR. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Diabetic Retinopathy

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 213 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>